1. Therapeutic Potential of Tpl2 (Tumor Progression Locus 2) Inhibition on Diabetic Vasculopathy Through the Blockage of the Inflammasome Complex
- Author
-
Po-Hsun Chen, Sheng-Mao Wu, Shing-Hwa Liu, Cheng Hsu Chen, Keng-Hung Lin, Maw-Rong Lee, Meei-Ling Sheu, Fu-Yu Lin, Chin-Chang Shen, Wen-Jane Lee, Wayne Huey-Herng Sheu, De-Wei Lai, Hsiang-Yu Yeh, and Jun-Sing Wang
- Subjects
Male ,0301 basic medicine ,Databases, Factual ,Inflammasomes ,medicine.medical_treatment ,Angiogenesis Inhibitors ,Inflammation ,Retinal Pigment Epithelium ,Retinal Neovascularization ,Diabetes Mellitus, Experimental ,Neovascularization ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pregnancy ,Proto-Oncogene Proteins ,medicine ,Animals ,Humans ,Prospective Studies ,Protein Kinase Inhibitors ,Cells, Cultured ,Aged ,Diabetic Retinopathy ,Retinal pigment epithelium ,business.industry ,Inflammasome ,Retinal ,Diabetic retinopathy ,Middle Aged ,MAP Kinase Kinase Kinases ,medicine.disease ,Mice, Inbred C57BL ,Cross-Sectional Studies ,Diabetes Mellitus, Type 1 ,030104 developmental biology ,medicine.anatomical_structure ,Cytokine ,Diabetes Mellitus, Type 2 ,chemistry ,030221 ophthalmology & optometry ,Cancer research ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Inflammasome complex ,Signal Transduction ,medicine.drug - Abstract
Objective: Diabetic retinopathy, one of retinal vasculopathy, is characterized by retinal inflammation, vascular leakage, blood-retinal barrier breakdown, and neovascularization. However, the molecular mechanisms that contribute to diabetic retinopathy progression remain unclear. Approach and Results: Tpl2 (tumor progression locus 2) is a protein kinase implicated in inflammation and pathological vascular angiogenesis. N Ɛ -carboxymethyllysine (CML) and inflammatory cytokines levels in human sera and in several diabetic murine models were detected by ELISA, whereas liquid chromatography–tandem mass spectrometry analysis was used for whole eye tissues. The CML and p-Tpl2 expressions on the human retinal pigment epithelium (RPE) cells were determined by immunofluorescence. Intravitreal injection of pharmacological inhibitor or NA (neutralizing antibody) was used in a diabetic rat model. Retinal leukostasis, optical coherence tomography, and H&E staining were used to observe pathological features. Sera of diabetic retinopathy patients had significantly increased CML levels that positively correlated with diabetic retinopathy severity and foveal thickness. CML and p-Tpl2 expressions also significantly increased in the RPE of both T1DM and T2DM diabetes animal models. Mechanistic studies on RPE revealed that CML-induced Tpl2 activation and NADPH oxidase, and inflammasome complex activation were all effectively attenuated by Tpl2 inhibition. Tpl2 inhibition by NA also effectively reduced inflammatory/angiogenic factors, retinal leukostasis in streptozotocin-induced diabetic rats, and RPE secretion of inflammatory cytokines. The attenuated release of angiogenic factors led to inhibited vascular abnormalities in the diabetic animal model. Conclusions: The inhibition of Tpl2 can block the inflammasome signaling pathway in RPE and has potential clinical and therapeutic implications in diabetes-associated retinal microvascular dysfunction.
- Published
- 2020
- Full Text
- View/download PDF